Diabetes mellitus is a chronic heterogeneous metabolic disease characterized primarily by hyperglycemia due to impaired insulin secretion or impaired insulin efficacy. In recent years, a number of novel point-of-care platforms have been developed for sustained and controlled drug delivery. These platforms allow the patients to ingest insulin via transbuccal, nasal, inhalation, transdermal or subcutaneous routes, thereby effectively releasing insulin molecules the need for inconvenient and frequent needle injections. There are several issues needed to be addressed in developing such as platform: How many routes of administration are available for a point-of-care medication platform? What device components and configurations are available? What is the status of their application? This review will highlight our early attempts to address these questions. It is expected this review could provide a comprehensive overview of the medication platforms for diabetes, as well as open new avenues for developing the next-generation drug delivery devices for patients with diabetes.

糖尿病是一种慢性异质性代谢性疾病，其主要特征是由于胰岛素分泌受损或胰岛素功效受损导致的高血糖症。近年来，已经开发了许多用于持续和受控药物输送的新型床旁平台。这些平台允许患者通过经颊、经鼻、吸入、经皮或皮下途径摄取胰岛素，从而有效地释放胰岛素分子，从而避免不方便和频繁的针头注射。平台等开发需要解决的几个问题：即时用药平台有多少种给药途径？有哪些设备组件和配置可用？他们的申请状态如何？这篇评论将重点介绍我们为解决这些问题所做的早期尝试。预计这篇综述可以全面概述糖尿病药物平台，并为开发用于糖尿病患者的下一代药物输送设备开辟新途径。